Event Brief
Revolution Medicines pill daraxonrasib shows improved survival
Filed: May 29, 2026 at 7:04 PM ET
Summary: Trial results for daraxonrasib report 13.2-month overall survival versus 6.7 months with standard chemotherapy.
WHO: Revolution Medicines
WHAT: Clinical trial testing of daraxonrasib, a RAS inhibitor targeting KRAS, reports improved overall survival in pancreatic cancer.
WHEN: May 29, 2026 at 6:00 PM ET
WHERE: Location not specified
WHY: The trial data show higher overall survival for patients receiving daraxonrasib than for those on standard chemotherapy.
ℹ️ This event is analyzed using pattern arcs, velocity indicators, and source analysis in our MI Console.
📋 This story has 3 earlier reports
🔍 9 sources analyzed
Know more. Read less.
The BriefBrief follows the story, so you don't have to read every article. See what happened, how it changed, and where it came from, all in one place.
Same format. Every time.
See how stories unfold →